EPISODE · Jul 6, 2023 · 1H 37M
Ghassan Abou-Alfa, MD, MBA - Renovating the Clinical Rulebook for HCC: Multidirectional Management With Innovative Immunotherapy and Targeted Platforms
from PeerView Clinical Pharmacology CME/CNE/CPE Video · host PVI, PeerView Institute for Medical Education
Go online to PeerView.com/UUY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Approaches to managing patients with hepatocellular carcinoma (HCC) are undergoing renovation! A recent wave of improved therapeutic regimens, including immunotherapy/anti-VEGF combinations (eg, atezolizumab and bevacizumab), dual immunotherapy combinations (ie, durvalumab-tremelimumab), and next-generation TKIs (ie, lenvatinib) has been introduced in the upfront setting. Recent additions to the second-line setting have delivered improved options for patients with HCC including immune checkpoint inhibitors (eg, pembrolizumab and tislelizumab) and multikinase inhibitors (ie, cabozantinib and regorafenib). Emerging data on other up-and-coming targeted platforms are forthcoming, including evidence for perioperative applications in earlier disease settings. With all of these developments, how should we update our clinical rulebooks for treating HCC? This activity, based on a recent live symposium, uncovers innovative treatment strategies in early and intermediate HCC and presents validated and emerging strategies in advanced HCC. The unique Tumor Board format uses case-based scenarios to facilitate an interactive discussion covering practical guidance you can use to renovate your own clinical rulebook. Upon completion of this activity, participants should be better able to: Examine the latest clinical evidence supporting the use of immunotherapy, targeted therapy, and combination regimens for the management of HCC; Integrate individualized treatment plans for patients with HCC based on the latest clinical evidence, expert recommendations, and patient-specific factors; and Employ team-based strategies and practical considerations when integrating novel HCC regimens, including monitoring, patient consultation, and adverse event management
What this episode covers
Go online to PeerView.com/UUY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Approaches to managing patients with hepatocellular carcinoma (HCC) are undergoing renovation! A recent wave of improved therapeutic regimens, including immunotherapy/anti-VEGF combinations (eg, atezolizumab and bevacizumab), dual immunotherapy combinations (ie, durvalumab-tremelimumab), and next-generation TKIs (ie, lenvatinib) has been introduced in the upfront setting. Recent additions to the second-line setting have delivered improved options for patients with HCC including immune checkpoint inhibitors (eg, pembrolizumab and tislelizumab) and multikinase inhibitors (ie, cabozantinib and regorafenib). Emerging data on other up-and-coming targeted platforms are forthcoming, including evidence for perioperative applications in earlier disease settings. With all of these developments, how should we update our clinical rulebooks for treating HCC? This activity, based on a recent live symposium, uncovers innovative treatment strategies in early and intermediate HCC and presents validated and emerging strategies in advanced HCC. The unique Tumor Board format uses case-based scenarios to facilitate an interactive discussion covering practical guidance you can use to renovate your own clinical rulebook. Upon completion of this activity, participants should be better able to: Examine the latest clinical evidence supporting the use of immunotherapy, targeted therapy, and combination regimens for the management of HCC; Integrate individualized treatment plans for patients with HCC based on the latest clinical evidence, expert recommendations, and patient-specific factors; and Employ team-based strategies and practical considerations when integrating novel HCC regimens, including monitoring, patient consultation, and adverse event management
NOW PLAYING
Ghassan Abou-Alfa, MD, MBA - Renovating the Clinical Rulebook for HCC: Multidirectional Management With Innovative Immunotherapy and Targeted Platforms
No transcript for this episode yet
Similar Episodes
No similar episodes found.